Analeah leads translational research at Inhibrx and is responsible for multiple IND filings annually. Prior to joining Inhibrx she spent ten years at Novartis in biologics drug discovery in multiple roles from oncology target validation through candidate optimization for varied therapeutic modalities, including antibody drug conjugates and immune activating agents. Analeah holds a doctorate degree from the University of California, San Francisco in biochemistry and molecular biology and completed her postdoctoral research at the Genomics Institute for the Novartis Research Foundation.
Stuart leads process development and product manufacturing activities at Inhibrx, including sub-teams for upstream and downstream process development and analytical and formulation development. His team internally produces and characterizes materials for efficacy, PK, and exploratory and GLP toxicology studies and works with contract organizations for the production and release of materials for clinical studies. Prior to joining Inhibrx, Stuart led teams of engineers and scientists developing novel protein production platforms at Sutro Biopharma and Ambrx and worked on experimental growth factor, antibody, and antibody drug conjugate therapies. Stuart received his Ph.D. in chemical engineering from Cornell University.
John leads single domain antibody discovery projects and biotherapeutic development at Inhibrx. He has been instrumental in developing Inhibrx’s multispecific antibody formats for conditional immune activation. John directs many aspects of research at Inhibrx including protein engineering, assay development, and new technologies. Prior to joining Inhibrx in 2010, John completed his postdoctoral training in Jack Dixonâ€™s laboratory in the Department of Pharmacology at UCSD. John received his Ph.D. from the UCSD Biomedical Sciences Program, performing his thesis research in the laboratory of Guy Salvesen at the Sanford-Burnham-Prebys Medical Discover Institute.
Klaus leads the clinical translation of Inhibrxâ€™s biotherapeutic pipeline. Prior to joining Inhibrx, Klaus trained at M.D. Anderson Cancer Center as a fellow and worked at Banner M.D. Anderson Cancer Center as a medical oncologist, where he also served as the local principal investigator of cancer immunotherapy trials. Klausâ€™s scientific work at Genentech and the Genomics Institute of the Novartis Research Foundation (GNF) focused on drug discovery and predictive biomarker development. Klaus received the highest academic honors and was a Scholar of the German Merit Foundation. He received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.
Quinn leads the target identification, validation and therapeutic lead selection and oversees the development strategy for Inhibrxâ€™s biotherapeutic pipeline. Prior to founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Quinn lead groups of Ph.D./M.D. level investigators in the conception and development of novel target identification and validation platforms. Quinn lead the first therapeutic antibody from GNF to transition from bench-top to clinical trials. His research on cell death at the Stanford-Burnham-Prebys Medical Discovery Institute was highly cited. Quinn received his Ph.D. in biochemistry from the University of Utah School of Medicine.
Brendan is a co-founder of Inhibrx and serves as its Chief Operating Officer and VP of Biotherapeutics. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporation strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine.
Mark founded Inhibrx with Brendan Eckelman and Quinn Deveraux in 2010 and served as the Chief Executive Officer since the companyâ€™s inception. Mark has extensive expertise in the biotechnology industry with over twenty years of experience in investment management and building the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mark was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.